Why Is Arcutis Biotherapeutics Stock Up Today?

Arcutis Biotherapeutics (ARQT) rose 9.841% in the fifteen minutes after its Q2 2026 report. Revenue grew 59% year-over-year to $129.86 million, above the $118.85 million estimate, and EPS of $0.11 beat the $0.03 estimate. The company raised its full-year net product sales guidance to $525-540 million, up from $480-495 million, citing both unit-demand growth and improved pricing after rebates and discounts.

Arcutis is a commercial-stage dermatology company selling topical treatments for chronic inflammatory skin diseases under the ZORYVE brand, covering plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. CEO Frank Watanabe pointed to the continued strength of the ZORYVE franchise as the leading branded non-steroidal therapy across its three indications. The company also logged its seventh FDA approval since 2022, expanding ZORYVE cream 0.3% to pediatric plaque psoriasis patients as young as age 2, and has an FDA-accepted supplemental application for a ZORYVE cream formulation in infants as young as 3 months with atopic dermatitis, with a decision expected by February 2027.

Arcutis also added a new board member, former Mirum Pharmaceuticals CEO Chris Peetz, and is expanding its primary-care and pediatric sales force, with a field launch expected by the end of August 2026.